Transfer of Argatroban Business in Europe

1/2 June 17th, 2024 Transfer of Argatroban Business in Europe Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo -ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group, announced has entered into an agreement with Ethypharm (Saint Cloud, Paris; CEO: Denis Delval) on June 13 th 2024 for the transfer of business of the selective antithrombin agent, argatroban monohydrate (argatroban) in Europe. Under MTPC's strategic focus on Radicava (generic name: edaravone), treatment agent for amyotrophic lateral sclerosis, within its European operations, it has been decided to transfer the argatroban business to Ethypharm. In Europe, MTPC’s subsidiary, Mitsubishi Tanabe Pharma Europe Ltd (hereinafter referred to as "MTPE," located in London, United Kingdom), and MTPE's subsidiary, Mitsubishi Tanabe Pharma GmbH (hereinafter referred to as "MTPD," located in Duesseldorf, Germany), have been actively involved in the marketing and sales of argatroban in United Kingdom and Germany, among other European countries, through their respective networks of partners. Ethypharm, known for its expertise in Europe in essential drugs in the field of CNS diseases (severe pain and addiction) and Hospital Injectables, aims to strengthen its established pharmaceutical business in Europe through the acquisition of MTPC group's European argatroban business. Furthermore, it intends to contribute to meeting the healthcare needs of various European countries through the provision of argatroban supply. MTPC group remains committed to delivering pharmaceutical products to patients in Europe through MTP E and MTPD, including the continued supply of Radicava. etc., thereby making a meaningful contribution to those facing diseases in the region. Contact: Mitsubishi Chemical Group Corporation Communications Division Osaka Communications Department +81-6-6205-5119 2/2 ■About Argatroban: Argatroban is a selective antithrombin agent developed by MTPC and is currently marketed in Japan under the name "Novastan." In Europe, it first received approval in Sweden in 2004 and is presently available as a treatment for heparin-induced thrombocytopenia (HIT) type II in 13 countries, including Germany, United Kingdom, France, Spain and Italy. "Heparin-induced thrombocytopenia (HIT) type II " is a severe condition that carries the risk of fatal thromboembolic complications. Argatroban is an anticoagulant with a short half-life in the bloodstream and undergoes metabolism in the liver, making it suitable for patients post-surgery and those with kidney disease who may develop HIT type II. ■About Ethypharm: Ethypharm is a leading mid-sized international pharmaceutical company , with strong European roots, that manufactures and provides essential drugs, with a focus on hospital care, c entral nervous system (severe pain and addiction) and internal medicine. Its commitment is to impro ve patients’ lives and make a positive impact on society and the environment. Ethypharm has 1,700 employees dedicated to its various pharmaceutical activities, of which 1,400 are in industrial operations . The six production sites located in France, the UK, Spain, and China have expertise in injectables and complex oral solid forms.

The release as fetched from its publisher. tanabe-pharma.com ↗